Hematopoietic stem cells in the bone marrow (BM) give rise to all blood cells. According to the classic model of hematopoiesis, the differentiation paths leading to the myeloid and lymphoid lineages segregate early. A candidate 'common lymphoid progenitor' (CLP) has been isolated from CD34 þ CD38 À human cord blood cells based on CD7 expression. Here, we confirm the B-and NK-differentiation potential of CD34 þ CD38 À CD7 þ cells and show in addition that this population has strong capacity to differentiate into T cells. As
Introduction
All blood cells ultimately derive from a rare population of hematopoietic stem cells in the bone marrow (BM) that are multipotent and have the ability to self-renew. According to the classic model of hematopoiesis, all lymphoid cells (T, B and natural killer (NK) cells) develop through a common precursor stage, the so-called 'common lymphoid progenitor' (CLP), and accordingly, cells from the myeloid lineages share a 'common myeloid progenitor' (CMP). This model was supported by the prospective isolation of cell populations with CLP and CMP function from the murine BM.
1,2 Recent evidence, however, indicated that BM CLPs are not physiological T-cell progenitors, as early thymic progenitors (ETPs) do not have the CLP phenotype 3 and CLPs are not present in the peripheral blood. 4 Instead, the thymus is most likely seeded by a multipotent progenitor. During fetal hematopoiesis, B and T cells do not share a direct common progenitor either, as CLPs were not found in the fetal liver. 5 Instead, fetal B and T cells would develop through B/myeloid and T/myeloid intermediates.
The first report of a human CLP came from Galy et al. 6 who showed that a subpopulation of adult and fetal BM Lin À CD34 þ cells expressing the early B-and T-cell marker CD10 is not capable of generating monocytic, granulocytic, erythroid or megakaryocytic cells, but can differentiate into dendritic cells, B, T and NK cells. These Lin À CD34 þ CD10 þ cells homogenously expressed CD38. According to Ishii et al. 7 expression of the chemokine receptor CXCR4 on BM CD34 þ cells would be sufficient to restrict their differentiation potential to the lymphoid lineage. A human CMP was recently also identified in the Lin À CD34 þ CD38 þ fraction of BM and cord blood. These CMPs are CD45RA À and express low levels of IL-3Ra. 8 In cord blood, expression of CD10 on CD34 þ cells does not discriminate progenitor cells with lymphoid-restricted potential from multipotent cells. 9 However, Hao et al. 9 detected in the most primitive CD34 þ CD38 À cord blood fraction a subpopulation expressing CD7, an antigen that was previously identified on early human T-lymphoid progenitors, and they showed that single CD34 þ CD38 À CD7 þ cord blood cells can generate B cells, NK cells and dendritic cells, but are devoid of myeloid or erythroid differentiation potential. T-cell potential was not addressed by these investigators.
In a recent study, Haddad et al. 10 hi Lin À CD10 þ cells predominantly possess B-cell differentiation potential. Additionally, both populations retain some degree of myeloid differentiation capacity. Gene expression data from microarray analyses supported their conclusions.
In the present study, we confirm that the CD34 þ CD38 À CD7
þ cord blood population is lymphoid-committed and we show that it also has strong T-lymphoid differentiation potential in fetal thymus organ culture (FTOC). To investigate the molecular mechanisms driving lymphoid commitment, we studied the differential gene expression between CD34 þ CD38 À CD7 À multipotent cells and CD34 þ CD38 À CD7 þ CLP cells using Affymetrix GeneChip technology.
Materials and methods

Cell sorting
Cord blood was obtained and used following the guidelines of the Medical Ethical Commission of the Ghent University 
Co-culture on MS-5 stromal cells
The differentiation of stem cells to most lymphoid (except T cells) and myeloid cell types can be accomplished in vitro by culture in the presence of the appropriate human recombinant cytokines on a feeder layer of the murine stromal cell line MS-5.
11 Four days before their use in co-culture experiments, MS-5 cells (kindly provided by L Coulombel, Institut Gustave Roussy, Villejuif, France) were seeded in 96-well plates at a density of 5 Â 10 3 cells per well. Co-cultures were initiated by incubating human sorted cells in 200 ml Iscove's Modified Dulbecco's Medium (IMDM) (Invitrogen) supplemented with 5% human AB serum (Valley Biomedical, Winchester, VA, USA), 5% fetal calf serum (FCS), 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamin (all from Invitrogen) and the following cytokines: SCF (50 ng/ml), FL (50 ng/ml), TPO (10 ng/ml), IL-2 (5 ng/ml), IL-7 (20 ng/ml) and IL-15 (10 ng/ml) (mix 6) (all cytokines from R&D Systems, Abingdon, UK). After 20 days of culture at 371C and 7% CO 2 , the progeny of the cells was counted with a Bü rker hemocytometer excluding dead cells with Trypan blue, and their phenotype was determined by flow cytometry.
Fetal thymus organ culture
Thymic lobes were isolated from fetal day 15 nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice obtained from our own pathogen-free breeding facility. Animals were treated according to the guidelines of the Laboratory Animal Ethical Commision of the Ghent University Hospital. Each lobe was placed in a well of a Terasaki-plate and 25 ml complete IMDM medium containing 1000 human cells was added. The plates were inverted and incubated at 371C with 7% CO 2 for 72 h. After this 'hanging drop' culture, during which the precursor cells migrate into the thymic lobes, the lobes were transferred to a Nuclepore polycarbonate membrane (Whatman, Brentford, UK) on a Gelfoam sponge (Pharmacia & Upjohn, Kalamazoo, MI, USA) soaked in complete IMDM medium supplemented with 10% human AB serum and cultured for 32 days at 371C with 7% CO 2 . After the first 14 days, half of the medium was replaced with fresh medium. Thymocytes were harvested by mechanical disruption of the thymic structure and viable cells were counted by Trypan blue exclusion. Cells were stained with appropriate antibodies and analyzed by flow cytometry.
Flow cytometry
Before labelling with antibodies, cells were pre-incubated 15 min with anti-mouse FcRgII/III (clone 2.4.G2, a kind gift of Dr J Unkeless, Mount Sinai School of Medicine, New York, NY, USA) and human IgG (Miltenyi Biotec) to block murine and human Fc receptors, respectively. Cells were incubated with appropriate amounts of combinations of the following mouse anti-human monoclonal antibodies: CD19-PE, CD34-APC, CD4-APC, CD33-FITC, CD14-FITC (all from BD Biosciences), CD56-APC and CD8b-PE (both from Immunotech, Beckman Coulter, Fullerton, CA, USA). Cell populations containing mouse leukocytes (from FTOC) were simultaneously stained with anti-mouse CD45-CyChrome (BD Pharmingen, San Diego, CA, USA). After 45 min, cells were washed with ice-cold PBS þ 1% BSA þ 0.1% NaN 3 , propidium iodide (4 mg/ml) was added and cells were analyzed on a FACSCalibur. Propidium iodide positive and mouse CD45 þ cells, representing dead cells and mouse leukocytes, respectively, were excluded from analysis, which was performed with CellQuest software (BDIS).
RNA isolation and amplification
The TRIZOL lysates of different sorts, corresponding to a total of 100 000 sorted cells, were pooled and total RNA was extracted and purified on an RNeasy column (Qiagen, Venlo, The Netherlands) according to the instructions of the manufacturers. The RNA was concentrated to 10 ml with Microcon YM-50 columns (Millipore, Billerica, MA, USA) and subjected to Degenerative Oligonucleotide Primer-(DOP) mediated amplification. The detailed protocol, which was developed in our lab, is available upon request. Briefly, mRNA was first reverse transcribed using a T7-promoter oligo(dT) primer. After RNase H treatment, second strand synthesis was initiated using the 22-nt DOP-primer. In vitro transcription of the cDNA with T7 RNA-polymerase was carried out to generate cRNA, which was used in a second round of amplification using random hexamers for synthesis of the first strand, and the T7-promoter oligo(dT) primer for synthesis of the second strand. cDNA was transcribed and biotin-labelled using the ENZO BioArray HighYield RNA Transcript Labeling Kit (ENZO, Farmingdale, NY, USA) according to the manufacturer's instructions. Biotinylated cRNA was purified on an RNeasy column and its quality was determined on an Agilent 2100 BioAnalyzer (Agilent, Palo Alto, CA, USA). RNA isolation and amplification was performed twice for both CD34
Microarray analysis
Affymetrix microarray analysis was performed according to Minimum Information About a Microarray Experiment (MIAME) guidelines (www.mged.org/Workgroups/MIAME/miame.html). Biotinylated cRNA was fragmented and hybridized to Affymetrix GeneChip arrays according to the guidelines of the manufacturer. In a first experiment, biotinlylated cRNA was hybridized to Affymetrix HG-U133A arrays, while in a second experiment it was hybridized to Affymetrix HG-U133 Plus 2.0 arrays. Statistical analysis of the microarray data was performed as described before. 12 Briefly, after background removal and quantile normalization by Robust Multi-chip Average (RMA) analysis, 13 the raw perfect match (PM) probe intensity levels were used in a per probe set two-way analysis of variance (ANOVA) (with factors 'probe' and 'cell population') to generate an average expression level for the two biological repeats and a P-value for the significance of the difference between the
tions. The P-values were adjusted for multiple testing using Sidak step-down adjustment and differences with adjusted P o0.05 were considered significant.
Bioinformatics
The differentially expressed genes were categorized according to Gene Ontology (GO) terms using the Affymetrix NetAffx center (http://www.affymetrix.com/analysis/index.affx) and the freely available programs Onto-Express 14 and Ease (http:// david.niaid.nih.gov/david/ease.htm). Further information on the genes was gained by manually searching OMIM (http:// www.ncbi.nlm.nih.gov/entrez/query.fcgi?db ¼ OMIM) and GeneCard databases (http://www.genecards.org/), which both have links to PubMed literature references. Expression pattern information was derived from GeneNote, a database of human genes and their expression profiles in healthy tissues based on microarray experiments performed on the Affymetrix HG-U95 set (http://genecards.weizmann.ac.il/genenote/), and SymAtlas (http://symatlas.gnf.org/SymAtlas/). Mapping of the genes on pathways and networks was done using the commercial package Ingenuity Pathways Analysis (Ingenuity, Redwood City, CA, USA). MatchMiner (http://discover.nci.nih.gov/matchminer/ index.jsp) was used to find common genes in the lists of differentially expressed genes of our study and those of Dik et al. 12 and van Zelm et al.
15
Real-time PCR analysis
Total RNA was extracted from sorted cells using TRIZOL and was DNAse treated on an RNeasy column according to the manufacturer's guidelines. The RNA was concentrated with Microcon YM-50 columns and oligo(dT)-primed reverse transcription was performed with SuperScript II (Invitrogen). Realtime PCR analysis with Sybr Green I (Eurogentec, Seraing, Belgium) was performed with an ABI PRISM 7000 (Applied Biosystems, Foster City, CA, USA) using the standard temperature protocol (40 cycles of 10 min 951C, 15 s 951C, 60 s 601C). Reaction mixtures contained 300 nM of forward and reverse primers and 0.04% BSA (Sigma, St Louis, MO, USA). Primers were designed using Primer Express 2.0 software (Applied Biosystems) and sequences can be found in Supplementary  Table S4 . Expression levels were normalized to the expression of the reference gene HPRT using the DDC T method. 16 
Results
CD34
þ CD38 À CD7 þ cord blood cells generate high numbers of B and NK cells but few myeloid cells in co-cultures on MS-5 stromal cells
þ cord blood cells are committed to the lymphoid lineage, we stringently sorted both Figure 1 ) and determined their differentiation potential in MS-5 co-cultures with a mix of six cytokines (SCF, FL, TPO, IL-2, IL-7 and IL-15) permitting both lymphoid and myeloid differentiation. In initial experiments, we noticed that the CD7 À cells proliferated much faster than the CD7 þ cells. Therefore, even the slightest contamination of the CD7 þ population with CD7 À cells would obscure the real differentiation potential of the CD7 þ cells. For this reason, the sorted cells were plated at 10 cells per well, which ensures that most wells only contain CD7 þ cells. þ stem cells and differentiation towards monocytes, but also supports differentiation towards B and NK cells.
17 CD7 À cells proliferated well and most cells differentiated into the myeloid lineage (CD33 þ ), while also a low number of cells remained CD34 þ . On the contrary, the wells initiated with CD7 þ cells contained mainly B and NK cells, almost no CD34 þ cells and few myeloid cells. Absolute total cell numbers were 13-fold reduced compared to wells initiated with CD7 À cells. Remarkably, the proportion of B and NK cells in the different wells initiated with CD7 þ cells was highly variable, with most wells being enriched in either of the two cell types, and only five wells containing similar numbers of B and NK cells. This explains the large s.d. on the average frequencies of B and NK cells.
blood cells efficiently generate T cells in FTOC
The co-culture system on MS-5 stromal cells does not support T-cell differentiation. The capacity of the CD7 þ and CD7 À cells þ cells clearly had generated a higher percentage of double positive (DP) thymocytes than those initiated with CD7 À cells. Also from the absolute cell number it is clear that CD7
þ cells performed much better in FTOC than CD7 À cells: CD7 þ cells generated about 10 times more cells than the CD7 À cells (15 019775668 versus 14 549717 886). These data indicate that, as expected from a CLP, CD7 þ cells generate T cells with a much faster kinetics than the more immature CD7 À cells.
RNA amplification and microarray analysis
As a result of the rare nature of the CD34 þ CD38 À CD7 þ cord blood population, it was necessary to perform RNA amplification to obtain a sufficient amount of RNA to hybridize on the GeneChips. For each of two separate experiments, total RNA was isolated from a total of 100 000 sorted
À cells pooled from three to eight separate sorts, in each of which one to three cord blood units were pooled. This guaranteed a normalization of interindividual sources of variation.
In the first microarray experiment, cRNA was hybridized to Affymetrix HG-U133A arrays, which are comprised of more than 22 000 probesets representing 18 400 transcripts, including 14 500 well-characterized human genes. In the second experiment, cRNA was hybridized to Affymetrix HG-U133 Plus 2.0 arrays, which are comprised of more than 54 000 probesets representing 47 000 transcripts, including 38 500 well-characterized human genes. The expression values of the 22 215 common probesets in both experiments were used to calculate a correlation coefficient between the two biological repeats. As shown in Figure 4 , the correlation between the biological repeats was very high (correlation coefficients of 0.92 and 0.96 for the CD7 À and the CD7 þ arrays, respectively), which allowed us to use the average expression values of the two repeats for further analysis. Of the 22 215 probesets that were present on both GeneChips, 201 were significantly differentially expressed (adjusted Po0.05) (see Supplementary Table S1 ). Of these, 110 probesets representing 101 genes were upregulated in the CD7 þ population, while 91 probesets representing 89 genes were downregulated in the CD7 þ population. 
Validation of microarray data
The mRNA expression of the markers used for cell sorting, namely CD34, CD38 and CD7, as measured by the microarrays, correlated well with their cell surface expression on the sorted populations. To further validate the microarray data, the expression of 11 randomly chosen transcripts was analyzed by real-time PCR on unamplified RNA isolated from newly sorted cells. Except for RGS2, fold changes obtained by real-time PCR analysis correlated well with those obtained by the microarray analysis ( Figure 5 ). This indicates that the differences in gene expression detected by the microarray analysis are reliable and that the linear amplification of the RNA before the microarray analysis did not induce a bias in the relative presence of individual RNA molecules.
Analysis of the microarray data
Using annotation software, including Onto-Express, Ease and the NetAffx Analysis Center from Affymetrix, the significantly differentially expressed genes were grouped into functional categories (see Supplementary Tables S2 and S3 ). Figure 6 shows the GO terms of the categories Molecular Function, Biological Process and Cellular Component that have at least three genes annotated to them. Gene categories that are significantly over-represented in the list of upregulated genes include transcription factors, RNA-binding molecules, components of the ubiquitin-protein ligase complex, splice factors, transporters and signal transduction molecules. The list of downregulated genes is significantly enriched for structural components of the ribosome, components of the cytoskeleton, signal transduction molecules and molecules involved in protein biosynthesis and cell proliferation. The differentially expressed genes were also imported into Ingenuity Pathways Analysis software to identify functional relationships between genes based on known interactions in the literature (Table 1) . Interestingly, the biological function 'hematological system development and function' is associated with three of the four highest ranked biological networks. Next, we did an extensive literature survey for the differentially expressed genes. The gathered gene information is added to Supplementary Tables S2 and S3. About one-third of both upregulated and downregulated genes has been reported to be expressed in hematopoietic tissue. These genes are underlined. Remarkably, more than 75% of the differentially expressed transcription factors have been involved in hematopoiesis. In addition, many differentially expressed genes are involved in cell proliferation, gene expression regulation, cytoskeleton regulation and protein degradation. In the following paragraphs, we discuss these genes in more detail.
Genes involved in hematopoiesis
Several genes that were significantly upregulated in the CD7 þ population play an essential role in lymphoid development. IGHM, BTK, PRKCB1 and BCL6 are essential for B-cell development; SMARCA4 and SATB1 are essential for T-cell development, while ADA and TCF4 (alias E2-2) are required for both B-and T-cell development. Other upregulated genes with a known function in lymphoid cells include the chemokine receptor CCR9 and the trancription factors MEF2A and RUNX3. In addition, many significantly upregulated genes are highly expressed in lymphoid tissues, suggesting a possible role in lymphoid development. These include MCM3AP, TRAF3IP3, CHD3, ARHGAP25, FLJ22635, c11orf21, TRAF4, TNFAIP3, EVL, FLJ13197, BASP1 and ADAM28. Several other significantly upregulated genes are expressed in the hematopoietic system, namely BAALC, ITGA4 (alias CD49D), TRIB2, TNFAIP2, PSCD4, P2RY14, HLX1, EMR2, LRRFIP1, TRIM33, TRAF5, NALP1 and OSBPL3 (alias ORP3).
Among the significantly downregulated genes a considerable number of genes are affiliated to myeloid differentiation. For instance, the transcription factors TAL1 (alias SCL), CEBPB (alias NF-IL6), EVI1 and IFI16 are well known for regulating myeloid Molecular characterization of human cord blood CLP I Hoebeke et al development. TNFSF10 (alias TRAIL), RGS2 and DLK1 (alias Pref-1) are also assumed to be involved in myeloid differentiation. IL1B, PRG1, UROD, PRDX2 and ICAM4 are specifically expressed in myeloid cell types. In addition, several downregulated genes are expressed in myeloid leukemias, suggesting a possible role in myeloid development. These include MLLT3, BEX1, ARHGEF12, PTPN11 (alias SHP2), MN1 and S100A6 (alias Calcyclin). Several other significantly downregulated genes are expressed in the hematopoietic system, some of them also in the lymphoid lineage. Possibly the expression of these genes must be downregulated to allow lymphoid differentiation, while they might be upregulated in later stages of lymphoid development. This category of genes includes HMGB3, the transcription factors KLF2, ETV5 and ELF-1, the T-cell differentiation protein MAL, and the T-cell specific transcription factor GATA3. GATA3 is clearly downregulated in the CD7 þ population according to our real-time PCR data (see Figure 5) , although the downregulation detected by the microarray analysis was not statistically significant. Several of the downregulated genes might be associated with HSC function, and their downregulation might, therefore, be correlated with the onset of differentiation. For instance, long-term (LT) repopulating activity of HSCs is contained entirely in the HSC fraction expressing HMGB3, 18 and accordingly, LT-HSCs express higher levels of HMGB3.
19 Also NDN and MLLT3 are upregulated in LT-HSCs. 19 Elimination of reactive oxygen species by catalase (CAT) was recently shown to be required for HSC self-renewal 20 and accordingly, CAT is upregulated in LT-HSCs. 19 The downregulation of other transcripts implicated in oxidoreductase activity (PRDX2, ALDH6A1, AKR7A2 and FLJ22222) might also correlate with the loss of self-renewal capacity by the CD7 þ population. Other downregulated genes expressed in the hematopoietic system include ICAM2, BST2, TXNIP, CXCR4 and LEPR. 
Genes involved in proliferation and apoptosis
The list of upregulated genes contains many genes known to act as negative regulators of cell proliferation, including LPIN1 (Lipin1), MCM3AP, ATR, POLS, SMARCA4, MACF1, KNTC1, RBBP6, TRIB2 and NF1. Many downregulated genes, on the other hand, are positive regulators of cell proliferation. These include LEPR, IFI16, S100A6 (alias Calcyclin), CKS2, LAPTM4B, HSPA1A and several ribosomal proteins such as RPL35, RPS27, RPS27L, RPS6 and RPL36A. A decrease in the expression of mRNAs that encode ribosomal proteins accompanies shut-off of cell division. 21 However, some downregulated genes are negative regulators of cell proliferation: NDN, KHDRBS3 (alias T-STAR), TXNIP and GADD45A. In addition, several genes involved in apoptosis were differentially expressed: NALP1, RERE, TRAF4 and TRAF5 were upregulated, while PMAIP1 was downregulated. Overall, this expression pattern of positive and negative regulators of proliferation tends to point to an intrinsic lower proliferative capacity of the CD7 þ population compared to the CD7 À population.
Genes involved in transcription/translation regulation
In addition to transcription factors, also many other proteins involved in gene expression were differentially expressed. The list of significantly upregulated genes contains for instance many genes involved in splicing, such as HNRPA1, CCNL1, SFPQ, SF3B1, RNPC2, PNN and METTL3. EIF4A1 is a translation initiation factor, and NACA is required for the intracellular translocation of newly synthesized polypeptides. TPR is implicated in the import of proteins into the nucleus, SLC38A1 is an amino-acid transporter and the RNA helicase DDX21 is involved in ribosomal RNA synthesis. These types of genes are also found amongst the significantly downregulated genes: C20orf67, LSM5, KHDRBS3 (alias T-STAR), BZW2 and HSPA1A and CTDSPL (alias SCP3). The differential expression of factors of the transcription/translation machinery might be an important mechanism for regulating lymphoid-specific gene/protein expression in the CD7 þ CLP cells. There is evidence that alternative splicing of mRNA, which permits the generation of several proteins from one gene by alternative exon usage, can be modulated in a cell type-or developmental stage-specific way. 22 Tissue-specific splicing can be the result of concentration differences of ubiquitously expressed splicing factors, but tissue type-or developmental stage-specific splicing factors have also been described. 23 
Genes involved in regulation of the cytoskeleton
Many differentially expressed genes are involved in the regulation of the cytoskeleton. The list of upregulated genes contains MACF1, Palladin, TBCD and DOCK1. More cytoskeleton-related genes are significantly downregulated: PLS3, KIAA1102, TNS1, ACTN1, PIP5K1B, ARHGEF12, MARCKS, ACTR2, HSPB1 and GABARAPL1. Although little is known about the cytoskeleton of hematopoietic stem and progenitor cells, 24 it might be involved in the regulation of differentiation in several ways. The cytoskeleton is a scaffold for various signal transduction pathways. 25 In addition, alterations in its structure can lead to the relocation and clustering of certain cytoskeletonlinked surface molecules. Moreover, the cytoskeletal organization can regulate gene expression by controlling the nuclear import of certain transcription factors.
26 Table 1 Biological networks generated by Ingenuity Pathways Analysis Network  Genes in network  Score Top functions   1  ADA, BTK, C1QBP, CAT, CEBPB, CXCR4, EVI1, FHL2, GADD45A, H2-D1, HSPA1A, HSPB1,  IFI16, IFITM3, IL1B, IRF8, LR8, MAL, MIA, PHLPB, PMAIP1, PRKCB1, PTPN11, RGS2,  RPS6, RPS6KA2, S100A6, SERPINE2, SMARCA4, TCF4, TNFAIP2, TNFAIP3, TNFSF10,  TRA1, TRAF4 Genes in bold are differentially expressed in the microarray analysis. Only networks with a significance score of 3 or higher (Pp0.001) are shown.
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Genes involved in protein degradation
A number of genes coding for proteins involved in the ubiquitinproteasome system of proteolysis, were significantly upregulated: TNFAIP3 (alias A20), UBR2, TRIM33 and USP34. Other proteolytic enzymes that were upregulated are ADAM28 and DPEP2. Proteins degraded by the ubiquitin-proteasome pathway include cyclins and other regulators of the cell cycle, and transcription factors. 27 Protein degradation is thus a mechanism to regulate the concentration of many regulatory proteins.
Discussion
The CD7
þ subpopulation of CD34 þ CD38 À human cord blood cells was identified by Hao et al. 9 as a primitive CLP population with the ability to generate B, NK and dendritic cells, but with no potential for myeloid or erythroid differentiation. In the present study, we confirmed the B-and NK-differentiation potential of this cell population in a co-culture assay using MS-5 stromal cells. In addition, we showed that this cell population has strong T-cell differentiation potential in hybrid humanmouse FTOC. Therefore, CD34
þ CD38 À CD7 þ cord blood cells have full lymphoid differentiation potential and are true CLPs.
Gene expression profiling of CD34 þ CD38
À CD7 þ cells and their CD7
À counterparts using Affymetrix oligonucleotide microarrays revealed the differential expression of many transcription factors, cell cycle genes, signal transduction molecules and proteins involved in gene expression and cytoskeleton regulation. Many upregulated genes are lymphoid-affiliated, whereas many downregulated genes are related to the myeloid lineage. The majority (146 of 190) of the significantly differentially expressed genes are also differentially expressed between one or more consecutive differentiation stages of early human T-and B-cell development 12, 15 (Supplementary Table S5 ). Of those, 80 are differentially expressed during T-and B-cell development, 38 only during T-cell development and 28 only during B-cell development. For many of those genes the differential expression (up-or downregulation) between CD7 À and CD7 þ cells is the same as between cord blood CD34 þ Lin À and the most immature T-or B-cell stage (CD34 þ CD38 À CD1 À and pro-B, respectively). The preferential expression of lymphoid-affiliated genes in CD34 þ CD38 À CD7 þ cells is in agreement with gene expression studies on murine hematopoietic stem and progenitor cells, which showed that CLPs express markers of B, T and NK cells but no myeloid markers, and conversely, CMPs express granulocytic/monocytic and megakaryocytic/erythroid markers but no lymphoid markers. 28, 29 The low-level 'promiscuous' expression of lineage-specific genes before commitment to a particular lineage, is referred to as 'lineage priming'. 30 Upon commitment to a particular lineage, cells upregulate the appropriate lineage-specific genes, and suppress the inappropriate genes of the alternative lineages. Surprisingly, murine HSCs express many myeloid-affiliated genes but almost no lymphoidaffiliated genes, while their immediate progeny, multipotent progenitors (MPP), exhibit both myeloid and lymphoid promiscuity. 28, 29 Moreover, murine HSCs express a lot of genes affiliated to non-hematopoietic tissues, 29 which may explain their reported capacity to differentiate into non-hematopoietic cell types. 31 Consistent with these data, our list of significantly downregulated genes also contained a number of non-hematopoietic genes.
Our study is the first to describe a global gene expression profile of a human CLP. In their recent study, 10 Haddad et al. determined the gene expression in the related
þ cord blood population, but these cells were not selected for CD38 negativity. These CD34 þ
CD45RA
hi CD7 þ cells display strong NK-and T-cell potential, but also substantial myelo/erythroid potential. 10 This is not surprising because most CD34 þ CD45RA hi CD7 þ cells are CD38 þ and, as mentioned in the paper by Hao et al. 9 and as we noticed ourselves (data not shown), even low expression of CD38 on CD34 þ CD7 þ cells is sufficient to confer these cells myeloid differentiation potential. CD38 is a marker expressed on more mature progenitors of all lineages. Therefore, the CD34 þ CD45RA
hi CD7 þ population is presumably heterogeneous and contains both lymphoid-and myeloid-committed progenitors, which can also express low levels of the CD7 antigen. Accordingly, the CD34 þ CD45RA
hi CD7 þ population expresses increased levels of the T-cell receptor g chain (cDNAs TRG, TRGC2 and TRGV9), terminal deoxynucleotidyl transferase (DNTT), and strikingly many genes that are specifically expressed in myeloid cells: calgranulin A (S100A8), the macrophage colony stimulating factor receptor CD115 (CSF1R), the myeloid-specific transcription factor CEBP/D (CEBPD), and the neutrophil granule proteins lysozyme (LYZ), myeloperoxidase (MPO), elastase 2 (ELA2), azurocidin (AZU1), cathepsin G (CTSG) and proteinase 3 (PRTN3). None of these genes were expressed by our CD34 þ CD38 À CD7 þ population. Regarding T-cell differentiation, it is still an open question whether multipotent or lymphoid-committed progenitor cells home to the thymus. In addition to their T-cell differentiation potential, fetal CD34 hi
CD1a
À thymocytes possess strong NKcell potential, as well as B-and dendritic cell potential, but lack granulocyte/macrophage potential. 32 Weerkamp et al. recently showed that the adult CD34 þ CD1a À thymocyte subset has differentiation potential not only for B, NK and dendritic cells, but also for myeloid and erythroid lineages, 33 leading to the hypothesis that the adult human thymus is seeded by a multipotent stem cell-like progenitor instead of a CLP. Still, the multilineage differentiation capacity of both fetal and adult early thymocytes remains to be shown at the single cell level, thus the possibility exists that, analogously to the corresponding murine DN1 thymocyte stage (CD44 þ CD25 À ), 34 the human CD34 þ CD1a À thymic subset is heterogeneous and contains multiple progenitors with different differentiation potential. Recently, two possible models for seeding of the thymus have been discussed: 35 either a multipotent HSC-like cell seeds the thymus or multiple precursor cells with differential lineage differentiation capacities enter the thymus. Therefore, it might be possible that T-committed progenitors in the human thymus derive from CD34 þ CD38 À CD7 þ thymic immigrants, while the other thymic cell progenitors derive from other cells in the CD34 hi CD45RA hi CD7 þ cord blood population. In conclusion, molecular characterization of human cord blood CD34 þ CD38 À CD7 þ cells showed preferential expression of lymphoid-affiliated genes, which is compatible with the restricted potential of these cells to differentiate into T (this study), B, NK and dendritic cells (Hao et al. 9 and this study). In addition, gene expression analysis revealed several interesting genes for further study. Overexpression and RNA interference of selected genes will learn whether expression of these genes is critical for the developmental transition of multipotent stem cells to the CLP stage.
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